# EDGAR Filing Document

**Accession Number:** 0001835535
**File Stem:** 0000950170-25-084874
**Filing Date:** 2025-6
**Character Count:** 6983
**Document Hash:** e084d1fc4f6a006ee11b63f78500bd0c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-084874.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0000950170-25-084874

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250610

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nemirovsky Julian
- **CENTRAL INDEX KEY:** 0001835535

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38436
- **FILM NUMBER:** 251040512

**MAIL ADDRESS:**
- **STREET 1:** 35 EAST 62ND STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SIGA TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0001010086
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 133864870
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 31 EAST 62ND STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065
- **BUSINESS PHONE:** 212-672-9100

**MAIL ADDRESS:**
- **STREET 1:** 31 EAST 62ND STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SIGA PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19961108

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nemirovsky Julian<br><sub>(Last) (First) (Middle)</sub><br>C/O SIGA TECHNOLOGIES, INC.<br>31 EAST 62ND STREET<br><sub>(Street)</sub><br>NEW YORK, NY 10065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>SIGA TECHNOLOGIES INC [ SIGA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock, par value $.0001 per share | 2025-06-10 |  | M |  | 19084 | A | <sup>(1)</sup> | 62598 | D |  |
| Common Stock, par value $.0001 per share | 2025-06-10 |  | D<sup>(2)</sup> |  | 5725 | D | $6.22 | 56873 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2025-06-10 |  | M |  |  | 19084 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock, par value $.0001 per share | 19084 | $0 | 0 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2025-06-10 |  | A |  | 24116 |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock, par value $.0001 per share | 24116 | $0 | 24116 | D |  |

---

### Footnotes:

(1) Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis.

(2) Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 13, 2024. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs.

(3) The RSUs were granted on June 11, 2024, and fully vested on the date of the Company's 2025 annual meeting of stockholders.

(4) RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 7,235 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors.

(5) The RSUs fully vest on the date of the Company's 2026 annual meeting of stockholders.

**Signature:** /s/ Kevin Buckley, as Attorney-in-Fact  
**Date:** 2025-06-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**